Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2011 | 1 |
2012 | 1 |
2013 | 1 |
2021 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Utility of pattern recognition and multimodal imaging in the diagnosis and management of doyne honeycomb retinal dystrophy complicated with type one choroidal neovascular membrane.
BMJ Case Rep. 2021 Feb 1;14(2):e237635. doi: 10.1136/bcr-2020-237635.
BMJ Case Rep. 2021.
PMID: 33526522
Free PMC article.
Younger age at presentation, bilateral symmetry, typical distribution of drusen along the arcades in a radiating pattern, peripapillary involvement, scarring and atrophy at macula were suggestive of doyne honeycomb retinal dystrophy. The reduced vision …
Younger age at presentation, bilateral symmetry, typical distribution of drusen along the arcades in a radiating pattern, peripapillary invo …
Laser clearance of drusen deposit in patients with autosomal dominant drusen (p.Arg345Trp in EFEMP1).
Lenassi E, Troeger E, Wilke R, Tufail A, Hawlina M, Jeffery G, Webster AR.
Lenassi E, et al.
Am J Ophthalmol. 2013 Jan;155(1):190-8. doi: 10.1016/j.ajo.2012.07.003. Epub 2012 Oct 2.
Am J Ophthalmol. 2013.
PMID: 23036572
Patients were examined before treatment as well as 1, 3, 6, and 12 months after the procedure. Clinical assessment included visual acuity, fundus-controlled perimetry, spectral-domain optical coherence tomography, and autofluorescence imaging. ...
Patients were examined before treatment as well as 1, 3, 6, and 12 months after the procedure. Clinical assessment included visual ac …
Item in Clipboard
Responsiveness of choroidal neovascular membranes in patients with R345W mutation in fibulin 3 (Doyne honeycomb retinal dystrophy) to anti-vascular endothelial growth factor therapy.
Sohn EH, Patel PJ, MacLaren RE, Adatia FA, Pal B, Webster AR, Tufail A.
Sohn EH, et al.
Arch Ophthalmol. 2011 Dec;129(12):1626-8. doi: 10.1001/archophthalmol.2011.338.
Arch Ophthalmol. 2011.
PMID: 22159686
No abstract available.
Item in Clipboard
Cite
Cite